KSQ Therapeutics, Takeda to develop novel cancer immunotherapies

By The Science Advisory Board staff writers

January 13, 2021 -- KSQ Therapeutics has entered into a broad strategic collaboration with Takeda Pharmaceutical to research, develop, and commercialize novel immune-based therapies for cancer.

Under the agreement, KSQ has granted Takeda an exclusive, worldwide, royalty-bearing license to develop, manufacture, and commercialize cell and noncell therapy products that modulate targets identified using KSQ's CRISPRomics technology, a discovery engine that enables genome-scale, in vivo validated, unbiased drug discovery across broad therapeutic areas.

The deal includes two T-cell targets previously identified and validated by KSQ, with the potential to introduce two additional T-cell targets to the collaborations. The companies will collaborate to discover and develop therapeutics that modulate natural killer (NK) cell targets to be identified through the agreement.

KSQ and Takeda will collaborate on investigational new drug-enabling activities, while Takeda will lead clinical development to explore multiple modalities. Takeda will fund all development and commercialization activities. KSQ will have the option to participate in cost/profit sharing on one of the two products based on T-cell targets, in the U.S. and retain royalties on all non-U.S. sales for that product.

KSQ will receive upfront and potential preclinical milestone payments that may exceed $100 million. In addition, KSQ will be eligible to receive development and commercialization milestone payments reaching up to $400 million per program, as well as tiered royalties on net sales of each approved product.

Takeda to distribute Y-mAbs' cancer antibody treatment in Israel
Y-mAbs and Takeda Israel, a subsidiary of Takeda Pharmaceutical, have entered into an exclusive license and distribution agreement for the registration...
Elektrofi, Takeda partner to advance plasma protein therapeutics
Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.
Takeda opens new cell therapy manufacturing facility
Takeda Pharmaceuticals said it has opened a new 24,000-sq-ft research and development (R&D) cell therapy manufacturing facility at its R&D headquarters...
Takeda, Twist partner on biologics discovery
Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter